Status:
NOT_YET_RECRUITING
Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies
Lead Sponsor:
Hopital Foch
Conditions:
Interstitial Lung Disease
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Diffuse interstitial lung diseases (ILDs) represent a group of rare, heterogeneous disorders of various etiologies, all sharing a common histopathological feature: fibrotic remodeling of the pulmonary...
Detailed Description
From a pathophysiological perspective, the development of interstitial lung disease (ILD) involves progressive inflammation and fibrosis. These processes gradually remodel the structure of the pulmona...
Eligibility Criteria
Inclusion
- PID-PNE interest group (n= 30 patients): Adult subjects followed for chronic interstitial lung disease with a follow-up duration \> 1 year with at least one biological sample showing a circulating PNE level \> 300/mm3 during their follow-up, without any prescription of systemic corticosteroid therapy and antifibrotic agents (PIRFENIDONE and NINTENADIB) responsible for modulation of the eosinophil count.
- 15 patients followed for Idiopathic Pulmonary Fibrosis (IPF) and 15 patients with another etiology of ILD will be selected.
- PNE ILD control group (n= 30 patients): Adult subjects with ILD with a PNE level \< 150/mm3 during their follow-up, without any prescription of systemic corticosteroid therapy and antifibrotic agents (PIRFENIDONE and NINTENADIB). - Have signed a consent form.
- Be affiliated with a health insurance plan.
Exclusion
- Patients under 18 years of age
- Patients over 75 years of age
- Pregnant patients
- Subjects with eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
- Subjects with hypereosinophilic syndrome (NEP \> 1500/mm3)
- Subjects with chronic idiopathic eosinophilic pneumonia (Carrington disease)
- Subjects with drug-induced interstitial lung disease
- Subjects with respiratory failure (acute and chronic: SaO2 \> 92% throughout the procedure)
- Subjects with unstable heart disease
- Subjects with severe comorbidities
- Subjects receiving oxygen therapy
- Subjects deprived of liberty or under guardianship -Patients subject to a guardianship and judicial safeguard measure
- PID-PNE or non-PID PNE patients receiving systemic corticosteroid therapy or antifibrotic treatment (PIRFENIDONE and NINTENADIB)
Key Trial Info
Start Date :
May 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2029
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06980844
Start Date
May 31 2025
End Date
February 28 2029
Last Update
May 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Drci Foch Hospital
Suresnes, Suresnes, France, 92160